Best Laid Plans: Pfizer's Torcetrapib Tanks

Pfizer's decision to discontinue the development of it's Phase III high-density lipoprotein-boosting torcetrapib in early December leaves the Big Pharma with little choice but to accelerate its restructuring plans and start spending some of its estimated $34 billion cash reserves to bolster its pipeline.

By Christopher Morrison and Roger Longman

Pfizer Inc.'s decision to discontinue the development of it's Phase III high-density lipoprotein-boosting torcetrapib in early December leaves the Big...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Business Strategy

More from In Vivo